Description
The PEmax mRNA expresses an optimized prime editor enzymatic protein, which further increased editing efficiency in synergy with PE4, PE5 and engineered pegRNAs (Chen P, et al. 2021, Cell 184, 5635-5652). After efficient delivery into cells or animals, PEmax mRNA can translate into protein including a nickase and reverse transcriptase function for gene editing in cells.
This mRNA features:
- A Cap 1 structure with high capping efficiency
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response
- GenScript’s patented UTR to enhance translation
- A 100A poly(A) tail to mimic natural mature mRNA |
Form |
Liquid |
Concentration |
1mg/mL |
Full mRNA length |
6660nt |
Full mRNA Molecular Weight |
2.15 X 10^6 Da |
Storage buffer |
1mM Sodium citrate, pH6.5 |
Storage condition |
Store at -20°C for short term (<3 months), store at -80°C for long term. |
Appearance |
Clear and free of foreign particles |
RNA Length |
Expected size band detected |
RNA Content |
Target ± 5% |
Integrity |
≥ 75% |
OD260/OD280 |
1.70 ~ 2.30 |
Capping Efficiency |
≥ 90% |
Endotoxin |
< 10 EU/mg |
pH |
Target ± 0.5 |
Transfect a total of 2 µg of PEmax mRNA and pegRNA per well, using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.